All Open Clinical Trials

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Genomically-Guided Treatment Trial in Brain Metastases

A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.

A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in 
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.

COG-ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Feasibility Phase - Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≥ 2 years and ≤ 25 years of age at the time of enrollment.
All patients > 21 years of age at the time of enrollment must have had initial diagnosis of low-grade glioma by 21 years of age.

COG ACNS2021

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.

COG ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Patients must be ≥ 12 months and ≤ 21 years of age at the time of enrollment.

COG ACCL2031

A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas

Patients must be ≥ 3 years and < 30 years at the time of enrollment on screening.

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation

Protocol NRG-BR009, A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) (NCT05879926)

NRG-BR008, "A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer” (HERO)

 A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen)

WF-2202, Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial

EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

A211801 - BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

NRG CC011-Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)

EAQ222CD: “Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients”

A RANDOMIZED TRIAL ADDRESSING CANCER-RELATED FINANCIAL HARDSHIP THROUGH
DELIVERY OF A PROACTIVE FINANCIAL NAVIGATION INTERVENTION (CREDIT)

Blinded Reference Set for Multicancer Early Detection Blood Tests

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

WF-2202, Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

REACHING RURAL CANCER SURVIVORS WHO SMOKE USING TEXT-BASED CESSATION INTERVENTIONS

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

S2205, ICE COMPRESS: RANDOMIZED TRIAL OF LIMB CRYOCOMPRESSION VERSUS CONTINUOUS COMPRESSION VERSUS LOW CYCLIC COMPRESSION FOR THE PREVENTION OF TAXANE-INDUCED PERIPHERAL NEUROPATHY
 

Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

URCC-19075 “Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)”

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

S2012:  Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.

A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER

A022106: “Phase II/III second-line NABPLAGEM vs. nab-paclitaxel/gemcitabine in BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial

A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS

A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial.

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus ChemoRadioTherapy for Early Rectal Cancer

 EA2212, “A Randomized Phase II Study of Perioperative Atezolizumab  +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer”

A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)

NRG-GU010 - Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

NRG-GU011, A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

NRG-GU013, The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer

PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)

SWOG - S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).”

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Renal Tumors Classification, Biology, and Banking Study 

Patients must be < 30 Years Old at the Time of Diagnosis

COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Patients must be ≤ 30 years old at study enrollment.

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

Phase III Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Age ≥ 11 Years and ≤ 45 Years on the Date of Randomization

COG ACNS2021

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] 

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS

A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III), a prospective phase II treatment trial

COG ARAR2221

A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)

Patients must be ≤ 21 years of age at the time of study enrollment.

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing    

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS

PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors

A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

COG-AALL2121: A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia

Age: Patients must be 1 month to < 6 years old at the time of study enrollment and must have had initial diagnosis of leukemia at < 2 years old.

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.

COG APAL2020SC

Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Patients must be less than 22 years of age at the time of study enrollment.

COG-ASCT2031: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)

Age: 6 months to <22 years at enrollment

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)

Non-Chemotherapy Treatment (ramucirumab plus pembrolizumab) or Usual Care forAdvanced Non-Small Cell Lung Cancer Following Immunotherapy

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI):  A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

 RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC:  RAPTOR trial

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sub-Studies to ALCHEMIST: E4512 and EA5142

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

 A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Patients must be 5 to 60 years of age at the time of enrollment.

COG ANHL1931

A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

This is an AYA protocol  ≥ 2 years

EAQ211: Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors

URCC-19075 “Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)”

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS

Genomically-Guided Treatment Trial in Brain Metastases

A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors

Cancer Moonshot Biobank Research Protocol

EAQ222CD: “Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients”

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

COG APEC1621F

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

COG-ACCL21C2: Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer

≥6 months and ≤37 years of age at time of enrollment

COG-ANHL2121: Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

Age: 180 days- <22 years (at time of study enrollment).

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

S2209 A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-drug Induction Regimens Followed by Double- or Single-Agent Maintenance

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

patients must be ≤ 30 years at the time of initial diagnosis with high-risk disease

COG ARST2031

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)

Patients must be ≤ 50 years of age at the time of enrollment.

COG AOST2031

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Patients must be < 50 years at the time of enrollment

COG- ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Patients must be ≤ 21 years at the time of enrollment.

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA